BASEL, SWITZERLAND – 9 June, 2016 – A novel new drug being developed to treat antibiotic-resistant lung infections shows significant promise for treating the often life-threatening mixed bacterial and fungal lung infections contracted by cystic fibrosis patients, according to research presented today by TGV-inhalonix at the 39th European Cystic Fibrosis Conference.
George Tetz, scientific and development advisor for the New York-based pharmaceutical company TGV-inhalonix, detailed the findings of the company’s most recent studies on its inhaled antimicrobial Mul-1867, which is the first drug candidate being developed to address the growing problem of mixed bacterial and mixed bacterial and fungal respiratory infections in cystic fibrosis patients.
“Mul-1867 is a breakthrough drug candidate that has shown significant promise in treating the chronic infections that lead to progressive decline in lung function and eventually respiratory failure in patients with cystic fibrosis,” Tetz told the conference.
He presented the company’s recent study of inhaled Mul-1867 on animals infected with acute drug-resistant mixes of bacterial and fungal isolates from patients with cystic fibrosis.
In the study, Mul-1867 provided 80 percent and greater protection against mortality from lung infections caused by a mix of Pseudomonas aeruginosa and Staphylococcus aureusbacteria and a bacterial-fungal mix of Pseudomonas aeruginosa and the fungi Candida albicans.
By comparison, mice treated with an aminoglycoside antibiotic widely used for the treatment of lung infections in cystic fibrosis patients had only a 50 percent survival rate in the experimental models.
“Mul-1867 is the first drug candidate in development that holds promise against resistant strains of bacteria, as well those infections caused by a mix of bacteria and fungi infections that plague cystic fibrosis patients,” Tetz said.
Cystic fibrosis is a progressive, genetic disease that causes mucus buildup that clogs the airways and traps bacteria, leading to infections, extensive lung damage and eventually, respiratory failure. According to the Cystic Fibrosis Foundation, the median predicted survival age in persons with cystic fibrosis in the United States is 39.3 years.
The U.S. Food and Drug Administration recently granted Mul-1867 Orphan Drug Designation based on early indications of its potential for fighting lung infections in cystic fibrosis patients. The special status is intended to provide incentives for the development of drugs and biologics to treat rare diseases.
TGV-inhalonix also believes Mul-1867’s unique mechanism offers broad potential for the treatment of various bacterial and fungal infections in the general population, including respiratory tract infections in COPD patients, ventilator-associated pneumonia and fungal pneumonia.